Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
A 281.71 2.81% 7.69
BIIB closed up 2.81 percent on Thursday, May 13, 2021, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BIIB trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Sell Signal Bearish 2.81%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.81%
Upper Bollinger Band Walk Strength 2.81%
Older End-of-Day Signals for BIIB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 6 hours ago
Upper Bollinger Band Resistance about 9 hours ago
60 Minute Opening Range Breakout about 10 hours ago
Non-ADX 1,2,3,4 Pullback Entry about 10 hours ago
Rose Above Previous Day's High about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Biogen Idec Inc. Description

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biotechnology Immunology Pain Disability Monoclonal Antibody Monoclonal Antibodies Lymphoma Alzheimer's Disease Multiple Sclerosis Psoriasis Degenerative Disease Specialty Drugs Degenerative Diseases Immune Disorders Hemophilia Neurodegenerative Diseases Neuropathic Pain Idiopathic Pulmonary Fibrosis Progressive Pulmonary Fibrosis Autoimmune Disorders Chronic Lymphocytic Leukemia Lymphocytic Leukemia Weston Clinical Trial Product Lupus Spinal Muscular Atrophy Immunosuppressants Interferon Cd20 Factor Vii Treatment Of Hemophilia Acorda Therapeutics Clinical Trial Products Lupus Nephritis Nephritis Plaque Psoriasis Portola Pharmaceuticals

Is BIIB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 363.92
52 Week Low 223.25
Average Volume 1,036,592
200-Day Moving Average 268.38
50-Day Moving Average 269.57
20-Day Moving Average 270.75
10-Day Moving Average 274.11
Average True Range 6.66
ADX 15.46
+DI 22.28
-DI 11.33
Chandelier Exit (Long, 3 ATRs ) 263.17
Chandelier Exit (Short, 3 ATRs ) 277.02
Upper Bollinger Band 280.99
Lower Bollinger Band 260.50
Percent B (%b) 1.04
BandWidth 7.57
MACD Line 2.19
MACD Signal Line 0.97
MACD Histogram 1.2268
Fundamentals Value
Market Cap 43.35 Billion
Num Shares 154 Million
EPS 30.38
Price-to-Earnings (P/E) Ratio 9.27
Price-to-Sales 2.86
Price-to-Book 3.49
PEG Ratio 6.24
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 295.06
Resistance 3 (R3) 294.06 288.61 292.84
Resistance 2 (R2) 288.61 285.21 289.11 292.09
Resistance 1 (R1) 285.16 283.11 286.89 286.16 291.35
Pivot Point 279.71 279.71 280.57 280.21 279.71
Support 1 (S1) 276.26 276.31 277.99 277.26 272.07
Support 2 (S2) 270.81 274.21 271.31 271.33
Support 3 (S3) 267.36 270.81 270.59
Support 4 (S4) 268.36